Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma Topic Center

Conference Coverage
DLBCL Progression Beyond Third-Line Therapy Linked to Rising Health Care Costs
04/02/2025
Grace Taylor, MS, MA
A retrospective study highlights the substantial economic burden of disease progression following third-line treatment in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A retrospective study highlights the substantial economic burden of disease progression following third-line treatment in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A retrospective study highlights...
04/02/2025
First Report Managed Care
News
From Indolent to Aggressive: Understanding Lymphoma Transformation
04/09/2024
Hannah Musick
“Histologic transformation of indolent lymphoma to aggressive lymphoma, most commonly DLBCL, represents a well-recognized event,” said researchers. “While work in the past decade has shed light on many of the genetic and biological changes of...
“Histologic transformation of indolent lymphoma to aggressive lymphoma, most commonly DLBCL, represents a well-recognized event,” said researchers. “While work in the past decade has shed light on many of the genetic and biological changes of...
“Histologic transformation of...
04/09/2024
First Report Managed Care
News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
Jolynn Tumolo
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
No Access to CAR-T Therapy Raises Mortality for Louisiana Medicaid Patients With DLBCL 
08/02/2023
Jolynn Tumolo
“The state of Louisiana currently does not have any institution which offers CAR-T therapy. Our Medicaid population is further disadvantaged by the fact that their insurance does not cover out-of-state services,” researchers said.
“The state of Louisiana currently does not have any institution which offers CAR-T therapy. Our Medicaid population is further disadvantaged by the fact that their insurance does not cover out-of-state services,” researchers said.
“The state of Louisiana...
08/02/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Jolynn Tumolo
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
Jolynn Tumolo
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
Jolynn Tumolo
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Julie Gould
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
Jolynn Tumolo
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023
Jordan Kadish
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
Industry Insights
News

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

Conference Coverage
Exploring the Biosimilar Regulatory Landscape and Future Marketplace Potential
04/14/2023
Hannah Musick
Presenters at AMCP 2023 examined the regulatory landscape of biosimilars in the United States, explored key influencers for the adoption, and outlined the practical considerations for use.
Presenters at AMCP 2023 examined the regulatory landscape of biosimilars in the United States, explored key influencers for the adoption, and outlined the practical considerations for use.
Presenters at AMCP 2023 examined...
04/14/2023
First Report Managed Care
News
Montana Passes Significant Health Policy Changes
05/05/2023
Keely Larson
A recent legislative session in Montana included notable policy changes for Medicaid reimbursement, abortion, transgender rights, behavioral health, and more. 
A recent legislative session in Montana included notable policy changes for Medicaid reimbursement, abortion, transgender rights, behavioral health, and more. 
A recent legislative session in...
05/05/2023
First Report Managed Care
Headshot of David Rosmarin, Tufts, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
JAK Inhibitor Results in Skin Repigmentation in Patients With Vitiligo
05/30/2023
Maria Asimopoulos
David Rosmarin, MD, vice chair of education and research, assistant professor, Tufts Medical Center, walks through findings from TRuE-V, a phase 3 program designed to investigate ruxolitinib's efficacy and safety in patients with vitiligo. 
David Rosmarin, MD, vice chair of education and research, assistant professor, Tufts Medical Center, walks through findings from TRuE-V, a phase 3 program designed to investigate ruxolitinib's efficacy and safety in patients with vitiligo. 
David Rosmarin, MD, vice chair...
05/30/2023
First Report Managed Care
News
Patient Access, Inspection Challenges Arise as Generic Oncology Drug Production Decreases
06/23/2023
Arthur Allen
An ongoing decline in generic oncology drug production has created medication access difficulties for US patients.
An ongoing decline in generic oncology drug production has created medication access difficulties for US patients.
An ongoing decline in generic...
06/23/2023
Pharmacy Learning Network
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use